Pharma BD Deal Intelligence

Kyowa Hakko Kirin Co., Ltd. / ProStrakan Group plc

2011 · Acquisition/Merger · $474M · Complete

Announcement Sentiment

Strongly positive

Kyowa Hakko Kirin acquired UK specialty pharma ProStrakan for £292M (~$474M), 130p/share, a 41% premium. Deal gave KHK a Western commercial platform with Sancuso and supportive-care oncology products. Closed April 21, 2011.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 15yr post-close.

Key facts

Announced Feb 21, 2011
Closed Apr 21, 2011
Deal value $474M
Deal type Acquisition/Merger
Therapeutic area Oncology supportive care, urology
Indications Oncology supportive care, urology
Key assets Sancuso (granisetron transdermal) and specialty oncology supportive care portfolio
Mechanism Transdermal 5-HT3 antagonist (Sancuso) + multi-product portfolio

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals